SCHEMBL16488576

SCHEMBL16488576

COc1ccc(/N=C/c2ccc(C)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100B P04271 1/20 0.72
PTGS2 P35354 4/20 0.62
PTGS1 P23219 2/20 0.62
CA12 O43570 2/20 0.62
CA2 P00918 2/20 0.62
CA9 Q16790 2/20 0.62
RELA Q04206 1/20 0.60
ALDH1A1 P00352 6/20 0.59
ACHE P22303 3/20 0.56
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
CYP1A2 P05177 1/20 0.47
TP53 P04637 1/20 0.47
THRB P10828 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11380636 1.00 S100B (0.72) S100BPTGS2PTGS1CA12CA2
SCHEMBL13038178 1.00 S100B (0.72) S100BPTGS2PTGS1CA12CA2
SCHEMBL269057 1.00 S100B (0.72) S100BPTGS2PTGS1CA12CA2
SCHEMBL10733285 0.92 S100B (0.82) S100BPTGS2PTGS1CA12CA2
SCHEMBL2010515 0.92 S100B (0.82) S100BPTGS2PTGS1CA12CA2
SCHEMBL12416630 0.92 S100B (0.82) S100BPTGS2PTGS1CA12CA2
SCHEMBL10412841 0.92 S100B (0.82) S100BPTGS2PTGS1CA12CA2
SCHEMBL10733277 0.92 S100B (0.82) S100BPTGS2PTGS1CA12CA2
SCHEMBL12416663 0.87 S100B (0.74) S100BPTGS2PTGS1CA12CA2
SCHEMBL255410 0.86 ALDH1A1 (0.74) S100BPTGS2PTGS1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3707132-B1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES UNIV PARIS SACLAY (FR) 2024-07-17 EP disclosed
US-11498901-B2 Hydrogenation of imines with Ru complexes FIRMENICH SA (CH) 2022-11-15 US disclosed
US-20210371382-A1 HYDROGENATION OF IMINES WITH RU COMPLEXES FIRMENICH SA (CH) 2021-12-02 US disclosed
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines Universite Paris-Saclay (FR) 2021-06-15 US disclosed
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES Universite Paris-Saclay (FR) 2020-08-13 US disclosed
WO-2019063952-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES UNIVERSITE PARIS-SUD (FR) 2019-04-04 WO disclosed
US-9745288-B2 Compounds and methods for treating cancer by inhibiting the urokinase receptor INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2017-08-29 US disclosed
US-20150051247-A1 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371382-A1 HYDROGENATION OF IMINES WITH RU COMPLEXES HRH3, HRH4, HRH2 S100B 4575/4885PTGS2 2800/4885PTGS1 3646/4885
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES ADH1C, ADH1A, ADH5 S100B 3594/4885PTGS2 3275/4885PTGS1 3129/4885
US-20150051247-A1 COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR PLAUR, PLAU, PLG S100B 2194/4885PTGS2 387/4885PTGS1 262/4885
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines ADH1C, PNMT, ADH1A S100B 3361/4885PTGS2 3092/4885PTGS1 2940/4885
US-11498901-B2 Hydrogenation of imines with Ru complexes HRH3, HRH4, HRH2 S100B 4575/4885PTGS2 2800/4885PTGS1 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.